156 related articles for article (PubMed ID: 10845700)
1. Cleavage of vimentin by different retroviral proteases.
Snásel J; Shoeman R; Horejsí M; Hrusková-Heidingsfeldová O; Sedlácek J; Ruml T; Pichová I
Arch Biochem Biophys; 2000 May; 377(2):241-5. PubMed ID: 10845700
[TBL] [Abstract][Full Text] [Related]
2. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.
Bagossi P; Sperka T; Fehér A; Kádas J; Zahuczky G; Miklóssy G; Boross P; Tözsér J
J Virol; 2005 Apr; 79(7):4213-8. PubMed ID: 15767422
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases.
Konvalinka J; Heuser AM; Hruskova-Heidingsfeldova O; Vogt VM; Sedlacek J; Strop P; Kräusslich HG
Eur J Biochem; 1995 Feb; 228(1):191-8. PubMed ID: 7883003
[TBL] [Abstract][Full Text] [Related]
4. Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase.
Bláha I; Tözsér J; Kim Y; Copeland TD; Oroszlan S
FEBS Lett; 1992 Sep; 309(3):389-93. PubMed ID: 1325379
[TBL] [Abstract][Full Text] [Related]
5. The RNA binding G-patch domain in retroviral protease is important for infectivity and D-type morphogenesis of Mason-Pfizer monkey virus.
Bauerová-Zábranská H; Stokrová J; Strísovsky K; Hunter E; Ruml T; Pichová I
J Biol Chem; 2005 Dec; 280(51):42106-12. PubMed ID: 16257973
[TBL] [Abstract][Full Text] [Related]
6. Specific in vitro cleavage of Mason-Pfizer monkey virus capsid protein: evidence for a potential role of retroviral protease in early stages of infection.
Rumlová M; Ruml T; Pohl J; Pichová I
Virology; 2003 Jun; 310(2):310-8. PubMed ID: 12781718
[TBL] [Abstract][Full Text] [Related]
7. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.
Eizert H; Bander P; Bagossi P; Sperka T; Miklóssy G; Boross P; Weber IT; Tözsér J
J Virol; 2008 Oct; 82(20):10111-7. PubMed ID: 18701588
[TBL] [Abstract][Full Text] [Related]
8. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.
Sperka T; Miklóssy G; Tie Y; Bagossi P; Zahuczky G; Boross P; Matúz K; Harrison RW; Weber IT; Tözsér J
J Gen Virol; 2007 Jul; 88(Pt 7):2052-2063. PubMed ID: 17554040
[TBL] [Abstract][Full Text] [Related]
9. Retroviral proteases.
Dunn BM; Goodenow MM; Gustchina A; Wlodawer A
Genome Biol; 2002; 3(4):REVIEWS3006. PubMed ID: 11983066
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor.
Katoh I; Yasunaga T; Ikawa Y; Yoshinaka Y
Nature; 1987 Oct 15-21; 329(6140):654-6. PubMed ID: 2821409
[TBL] [Abstract][Full Text] [Related]
11. Effect of serine and tyrosine phosphorylation on retroviral proteinase substrates.
Tözsér J; Bagossi P; Boross P; Louis JM; Majerova E; Oroszlan S; Copeland TD
Eur J Biochem; 1999 Oct; 265(1):423-9. PubMed ID: 10491200
[TBL] [Abstract][Full Text] [Related]
12. An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase.
Konvalinka J; Horejsí M; Andreánsky M; Novek P; Pichová I; Bláha I; Fábry M; Sedlácek J; Foundling S; Strop P
EMBO J; 1992 Mar; 11(3):1141-4. PubMed ID: 1547777
[TBL] [Abstract][Full Text] [Related]
13. Three active forms of aspartic proteinase from Mason-Pfizer monkey virus.
Zábranský A; Andreánsky M; Hrusková-Heidingsfeldová O; Havlícek V; Hunter E; Ruml T; Pichová I
Virology; 1998 Jun; 245(2):250-6. PubMed ID: 9636364
[TBL] [Abstract][Full Text] [Related]
14. A structural model for the retroviral proteases.
Pearl LH; Taylor WR
Nature; 1987 Sep 24-30; 329(6137):351-4. PubMed ID: 3306411
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of activity of the protease from bovine leukemia virus.
Ménard A; Leonard R; Llido S; Geoffre S; Picard P; Berteau F; Precigoux G; Hospital M; Guillemain B
FEBS Lett; 1994 Jun; 346(2-3):268-72. PubMed ID: 8013645
[TBL] [Abstract][Full Text] [Related]
16. The role of the S-S bridge in retroviral protease function and virion maturation.
Zábranská H; Tůma R; Kluh I; Svatos A; Ruml T; Hrabal R; Pichová I
J Mol Biol; 2007 Feb; 365(5):1493-504. PubMed ID: 17140600
[TBL] [Abstract][Full Text] [Related]
17. Specificity studies on retroviral proteinase from myeloblastosis-associated virus.
Strop P; Konvalinka J; Stys D; Pavlickova L; Blaha I; Velek J; Travnicek M; Kostka V; Sedlacek J
Biochemistry; 1991 Apr; 30(14):3437-43. PubMed ID: 1849425
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional structure of a monomeric form of a retroviral protease.
Veverka V; Bauerová H; Zábranský A; Lang J; Ruml T; Pichová I; Hrabal R
J Mol Biol; 2003 Oct; 333(4):771-80. PubMed ID: 14568536
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a retroviral protease in monomeric and dimeric states.
Wosicki S; Gilski M; Zabranska H; Pichova I; Jaskolski M
Acta Crystallogr D Struct Biol; 2019 Oct; 75(Pt 10):904-917. PubMed ID: 31588922
[TBL] [Abstract][Full Text] [Related]
20. Luminometric method for screening retroviral protease inhibitors.
Horáková D; Rumlová M; Pichová I; Ruml T
Anal Biochem; 2005 Oct; 345(1):96-101. PubMed ID: 16125122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
